Quest Diagnostics Secures CDC Contract To Support COVID-19 Research

Vandana Singh
1 min read
0
In this article:

  • The Centers for Disease Control and Prevention (CDC) has granted a contract to Quest Diagnostics Inc (NYSE: DGX) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis.

  • Quest was awarded the contract following a competitive bid. The total contract value with all options is valued at up to approximately $19.5 million.

  • The new agreement extends and broadens the scope of the company's contributions to the CDC's seroprevalence research.

  • Also Read: Quest Diagnostics Q4 Earnings, FY22 Reflects Lower Demand For COVID-19 Testing Services.

  • Quest to employ its comprehensive menu of COVID-19 antibody test and data analytics services to support population health research across 45 states and Puerto Rico.

  • The company's serological tests are authorized by the FDA for emergency use and aid in identifying antibodies produced in response to recent or prior infection and/or vaccination.

  • Quest will provide the data analysis to the CDC in a HIPAA-compliant manner to support public health analysis and reporting.

  • Price Action: DGX shares closed 0.56% higher at $143.05 during after-hours trading on Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories